Pacific Edge (ASX:PEB, NZE:PEB) noted that the "Genetic Testing in Oncology: Specific Tests" local coverage determination became effective on April 24 in the US, halting Medicare coverage of its Cxbladder tests, according to Monday's Australian and New Zealand bourse filings.
A Pennsylvania District Court Judge ruled that her court lacks the jurisdiction to hear the firm's claim against Medicare administrative contractor Novitas and the US Centers for Medicare and Medicaid Services.
Its advocacy efforts also did not yield a change to the effective date or retirement of the local coverage determination.
Pacific Edge currently generates around 60% of its US revenue from Medicare. It will not seek re-coverage of Cxbladder Detect as no new evidence has been published that can be submitted for reconsideration. Detect users will be required to move over to the Triage test.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。